Fig. 3: Using TCGA WGS and WXS data as validation reference for RNA-SM analysis.
From: Pan-cancer discovery of somatic mutations from RNA sequencing data
a Distributions of RNA-SM counts in different genic regions across the tumors as validated by the WXS/WGS data. b Distribution of RNA-SM counts for each type of allele substitution across the tumors as validated by the WXS/WGS data. c Percentage of validated RNA-SMs among all predicted ones in relation to read depth of the mutation sites. Specifically, the RNA-SMs were validated by TCGA WXS or WGS data. d DNA sequencing coverage of the RNA-SM sites in the WXS or WGS data. e Overlap of the DNA-SMs with the RNA-SMs. The DNA-SM counts in relation to RNA-seq read depth is presented on the left y-axis; the percentage of the DNA-SMs that overlapped with the RNA-SMs is presented on the right y-axis. f Percentage of validated RNA-SMs in relation to the GC content of the mutation sites. The GC content was determined from a 100 bp window surrounding a mutation site.
